A Phase I Study of Combination Therapy With Anti-CD19 and Anti-CD22 Immunotoxins (Combotox) in Adults With Refractory/Relapse Acute Lymphoblastic Leukemia

Trial Profile

A Phase I Study of Combination Therapy With Anti-CD19 and Anti-CD22 Immunotoxins (Combotox) in Adults With Refractory/Relapse Acute Lymphoblastic Leukemia

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Monoclonal antibody HD37 ricin chain A conjugate (Primary) ; Monoclonal antibody RFB4 ricin chain A conjugate (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top